Sobi

Sobi is an international biopharmaceutical company specialising in rare diseases.

Our mission is to develop and deliver innovative treatments and services to transform the lives of patients with rare diseases.

A strong and growing portfolio

We have become a leading company in haematology and particularly in haemophilia. We seek to challenge the status quo, optimise treatments, advance research, create sustainable access and provide global support for the management of haemophilia.

Immunology has long been the core of our business at Sobi. Our international immunology portfolio includes three fast-growing products, each addressing unmet medical needs. Building on our expertise in rare diseases, we continue to explore new external growth opportunities that will strengthen our business and our late-stage pipeline. This will enable us to continue to provide access to innovative treatments for more people suffering from rare diseases.

An integrated biopharmaceutical company

Sobi is a biopharmaceutical company with in-house capabilities ranging from late-stage research and development to manufacturing and supply of biologics, to enable market access and distribution of innovative treatments and services to rare disease patients.

A growing international presence

With our headquarters in Stockholm, in Sweden, the Sobi organisation covers more than 30 countries and provides treatments to patients in more than 70 countries around the world.

Geographic expansion is an important aspect of our strategy, which we are pursuing through acquisitions, greater market penetration and by establishing operations in new territories.

https://www.sobi.com/france/fr